Last $19.02 USD
Change Today +0.44 / 2.37%
Volume 590.8K
RGLS On Other Exchanges
As of 2:15 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kleanthis G. Xanthopoulos Ph.D.

Chief Executive Officer, President, Principal Financial & Accounting Officer and Director, Regulus Therapeutics Inc.
AgeTotal Calculated CompensationThis person is connected to 137 board members in 6 different organizations across 11 different industries.

See Board Relationships
As of Fiscal Year 2013


Dr. Kleanthis G. Xanthopoulos, Ph.D., has been the Chief Executive Officer and President of Regulus Therapeutics Inc., since January 2009 and also has been its Principal Financial & Accounting Officer since June 21, 2013. Dr. Xanthopoulos serves as the Managing Director of Life Science Investments at Novera Optics, Inc. He serves as Senior Vice President at Isis Pharmaceuticals, Inc. He serves as a Member of the Executive Board at BIOCOM, Inc. He founded Sente, Inc. ...

Read Full Background

Corporate Headquarters*

3545 John Hopkins Court
San Diego, California 92121

United States

Phone: 858-202-6300
Fax: --

Board Members Memberships*

Former Director
Founder and Director
Former Director and Member of Audit Committee
Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Chairman of the Board
Director, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee
Former Director


Stockholms universitet
Stockholms universitet
University of Thessaloniki

Other Affiliations*

Annual Compensation*

Total Annual Compensation$600,000

Stock Options*

All Other Compensation$4,540
Exercisable Options916,999
Unexercisable Options458,284
Total Number of Options1,595,283

Total Compensation*

Total Annual Cash Compensation$964,540
Total Short Term Compensation$600,000
Other Long Term Compensation$4,540
Total Calculated Compensation$2,641,363
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $19.02 USD +0.44


Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
Mark W. Schwartz Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at